Endometrial Cancer

The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.

Nearly one-third of older women who survived colorectal, endometrial or ovarian cancer reported lower extremity lymphedema, according to data published in JAMA Network Open.

Selinexor prolonged PFS compared with placebo among women with advanced or recurrent endometrial cancer, according to topline data released by the agent’s manufacturer.

Lenvatinib plus pembrolizumab conferred significantly longer PFS and OS than chemotherapy among women with advanced endometrial cancer, according to randomized, phase 3 trial results published in The New England Journal of Medicine.

Pembrolizumab showed strong and lasting antitumor activity in women with previously treated, advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer, according to a study in Journal of Clinical Oncology.

Coffee consumption may reduce the risk for endometrial cancer, according to a study published in The Journal of Obstetrics and Gynaecology Research.

In a study of patients with endometrial stromal sarcomas treated with aromatase inhibitors the objective response rate was more modest than expected, but a majority did achieve stable disease, according to a study presented at the ASCO Annual Meeting.

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.

Transvaginal ultrasound used to determine appropriateness of endometrial cancer biopsy missed nearly five times more cases of the disease among Black women vs. white women, according to a simulated cohort study published in JAMA Oncology.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed results from the TOTEM trial presented at the ASCO Annual Meeting.